NDATOPICALCREAM
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
SOOLANTRA (ivermectin) by Galderma is 12. First approved in 2014.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOOLANTRA (ivermectin 1% cream) is a topical antiparasitic agent approved for the treatment of inflammatory lesions of rosacea. The exact mechanism of action in rosacea is unknown, though ivermectin is well-characterized as an antiparasitic with activity against multiple parasitic organisms. It is applied once daily as a cream formulation with minimal systemic absorption.
$0.002BPart D
Peak7.5 years to LOEProduct is at peak lifecycle with modest Part D spending ($2M) and limited claims volume (2,721 in 2023), suggesting a stable but specialized dermatology asset with small commercial team.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At therapeutic doses, ivermectin cream is not expected to prolong QTc interval. 12.3 Pharmacokinetics Absorption The absorption of ivermectin…
Pharmacologic Class:
Antiparasitic
Indications
Worked on SOOLANTRA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.